Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Unknown 1Terminated 1Recruiting 1Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 1

Conditions

Multiple Myeloma 66Recurrence 20Neoplasms, Plasma Cell 8Primary Myelofibrosis 3Polycythemia Vera 3Myeloproliferative Disorders 3Renal Insufficiency 2Plasmacytoma 2Lymphoma, Non-Hodgkin 2Immunoglobulin Light-chain Amyloidosis 2Central Nervous System Neoplasms 2Waldenstrom Macroglobulinemia 1Unspecified Adult Solid Tumor, Protocol Specific 1Thrombocytosis 1Thrombocythemia, Essential 1Sarcoma, Kaposi 1Prostatic Neoplasms 1Pancreatic Neoplasms 1Optic Nerve Glioma 1Neurofibromatosis 1 1Neoplasms 1Medulloblastoma 1Lymphoma, Large B-Cell, Diffuse 1Lymphoma, B-Cell 1Leukemia, Plasma Cell 1Leukemia, Myeloid, Acute 1Leukemia, Megakaryoblastic, Acute 1Intraocular Lymphoma 1Hodgkin Disease 1Glioma 1

Interventions

Dexamethasone 12Melphalan 7Calcium Dobesilate 6Lenalidomide 5Bortezomib 5Cyclophosphamide 4miridesap 3ixazomib 2Doxycycline 2Biopsy 24-(N-methylamino)-4'-(2-(2-(2-fluoroethoxy)ethoxy)ethoxy)stilbene 2pomalidomide 1dexamethasone acetate 1dexamethasone 21-phosphate 1daratumumab 1carfilzomib 1birtamimab 1auricularum 1Vinorelbine 1Thalidomide 1Tacrolimus 1Pharmaceutical Preparations 1Interleukin-2 1Granulocyte-Macrophage Colony-Stimulating Factor 1Gemcitabine 1Filgrastim 1Etanercept 1Drug Evaluation 1Blood Specimen Collection 1Bendamustine Hydrochloride 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Amyloidosis × pomalidomide × Clear all
NCT03959358 2023-07-24

A Study to Desensitize Allergic Reactions to Treatments for Blood Disorders

University Health Network, Toronto

Phase 2 Completed
10 enrolled
Plasma cell

Amyloidosis, Multiple Myeloma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡